Knowledge Center

Article / 2012

New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit

Authors:
  • Colin Minchom
Source:
Drug Development and Delivery, October 2012
“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as Hovione, that can apply multiple platforms, to increase the probability of solving the problem, and deliver the desired outcome.”